1. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program;Shah;Cancer Res,2004
2. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework;Atkinson;Clin Pharmacol Ther,2001
3. Clinical validity of detecting circulating tumor cells by adnatest assay compared with direct detection of tumor mRNA in stabilized whole blood, as a biomarker predicting overall survival for metastatic castration-resistant prostate cancer patients;Danila;Cancer J,2016
4. Circulating tumor cells as an analytical tool in the management of patients with cancer;Danila Danila,2016
5. FDA/NCI/CMS Oncology Biomarker Qualification Initiative. Memorandum of understanding between the FDA, NCI, and CMS for the FDA/NCI/CMS Oncology Biomarker Qualification Initiative. Document MOU 225-06-8001. January 2006. Last updated April 30, 2009. Available from: http://www.fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMOUs/ucm115681.htm [accessed March 16, 2011].